主营构成（按产品）（天宇股份）
| 2024年中报 | 2023年年报 | 2023年中报 |
|---|
2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| CMO(元) | - | - | 231,001,664.79 |
| 仿制药原料药及中间体(元) | - | - | 1,066,156,907.91 |
| 制剂(元) | - | - | 42,778,016.85 |
| 降血糖类原料药及中间体(元) | - | 87,693,630.16 | - |
| 降血压类原料及中间体(元) | 743,642,607.54 | 1,627,378,186.42 | - |
| 降血脂类原料药及中间体(元) | - | 58,751,048.93 | - |
| 抗病毒原料及中间体(元) | - | 45,032,551.47 | - |
| 抗凝血类原料药及中间体(元) | 158,220,586.93 | 350,409,718.93 | - |
| 抗哮喘类原料及中间体(元) | - | 169,599,502.69 | - |
| 其他(元) | - | 188,405,472.87 | 6,440,246.90 |
| 营业成本(元) | |||
| CMO(元) | - | - | 95,488,745.04 |
| 仿制药原料药及中间体(元) | - | - | 698,554,921.84 |
| 制剂(元) | - | - | 13,572,875.13 |
| 降血糖类原料药及中间体(元) | - | - | - |
| 降血压类原料及中间体(元) | 480,961,621.19 | 1,001,580,220.71 | - |
| 降血脂类原料药及中间体(元) | - | - | - |
| 抗病毒原料及中间体(元) | - | - | - |
| 抗凝血类原料药及中间体(元) | 80,135,575.44 | 160,680,399.22 | - |
| 抗哮喘类原料及中间体(元) | - | - | - |
| 其他(元) | - | - | - |
| 毛利(元) | |||
| CMO(元) | - | - | 135,512,919.75 |
| 仿制药原料药及中间体(元) | - | - | 367,601,986.07 |
| 制剂(元) | - | - | 29,205,141.72 |
| 降血糖类原料药及中间体(元) | - | - | - |
| 降血压类原料及中间体(元) | 262,680,986.35 | 625,797,965.71 | - |
| 降血脂类原料药及中间体(元) | - | - | - |
| 抗病毒原料及中间体(元) | - | - | - |
| 抗凝血类原料药及中间体(元) | 78,085,011.49 | 189,729,319.71 | - |
| 抗哮喘类原料及中间体(元) | - | - | - |
| 其他(元) | - | - | - |
| 毛利率(%) | |||
| CMO(%) | - | - | 58.66 |
| 仿制药原料药及中间体(%) | - | - | 34.48 |
| 制剂(%) | - | - | 68.27 |
| 降血糖类原料药及中间体(%) | - | - | - |
| 降血压类原料及中间体(%) | 35.32 | 38.45 | - |
| 降血脂类原料药及中间体(%) | - | - | - |
| 抗病毒原料及中间体(%) | - | - | - |
| 抗凝血类原料药及中间体(%) | 49.35 | 54.14 | - |
| 抗哮喘类原料及中间体(%) | - | - | - |
| 其他(%) | - | - | - |
| 收入构成(%) | |||
| CMO(%) | - | - | 17.16 |
| 仿制药原料药及中间体(%) | - | - | 79.19 |
| 制剂(%) | - | - | 3.18 |
| 降血糖类原料药及中间体(%) | - | 3.47 | - |
| 降血压类原料及中间体(%) | 82.46 | 64.39 | - |
| 降血脂类原料药及中间体(%) | - | 2.32 | - |
| 抗病毒原料及中间体(%) | - | 1.78 | - |
| 抗凝血类原料药及中间体(%) | 17.54 | 13.87 | - |
| 抗哮喘类原料及中间体(%) | - | 6.71 | - |
| 其他(%) | - | 7.45 | 0.48 |
| 毛利构成(%) | |||
| CMO(%) | - | - | 25.46 |
| 仿制药原料药及中间体(%) | - | - | 69.06 |
| 制剂(%) | - | - | 5.49 |
| 降血糖类原料药及中间体(%) | - | 0.00 | - |
| 降血压类原料及中间体(%) | 77.09 | 76.74 | - |
| 降血脂类原料药及中间体(%) | - | 0.00 | - |
| 抗病毒原料及中间体(%) | - | 0.00 | - |
| 抗凝血类原料药及中间体(%) | 22.91 | 23.26 | - |
| 抗哮喘类原料及中间体(%) | - | 0.00 | - |
| 其他(%) | - | 0.00 | 0.00 |
| 营业收入(元) |
| CMO(元) |
| 仿制药原料药及中间体(元) |
| 制剂(元) |
| 降血糖类原料药及中间体(元) |
| 降血压类原料及中间体(元) |
| 降血脂类原料药及中间体(元) |
| 抗病毒原料及中间体(元) |
| 抗凝血类原料药及中间体(元) |
| 抗哮喘类原料及中间体(元) |
| 其他(元) |
| 营业成本(元) |
| CMO(元) |
| 仿制药原料药及中间体(元) |
| 制剂(元) |
| 降血糖类原料药及中间体(元) |
| 降血压类原料及中间体(元) |
| 降血脂类原料药及中间体(元) |
| 抗病毒原料及中间体(元) |
| 抗凝血类原料药及中间体(元) |
| 抗哮喘类原料及中间体(元) |
| 其他(元) |
| 毛利(元) |
| CMO(元) |
| 仿制药原料药及中间体(元) |
| 制剂(元) |
| 降血糖类原料药及中间体(元) |
| 降血压类原料及中间体(元) |
| 降血脂类原料药及中间体(元) |
| 抗病毒原料及中间体(元) |
| 抗凝血类原料药及中间体(元) |
| 抗哮喘类原料及中间体(元) |
| 其他(元) |
| 毛利率(%) |
| CMO(%) |
| 仿制药原料药及中间体(%) |
| 制剂(%) |
| 降血糖类原料药及中间体(%) |
| 降血压类原料及中间体(%) |
| 降血脂类原料药及中间体(%) |
| 抗病毒原料及中间体(%) |
| 抗凝血类原料药及中间体(%) |
| 抗哮喘类原料及中间体(%) |
| 其他(%) |
| 收入构成(%) |
| CMO(%) |
| 仿制药原料药及中间体(%) |
| 制剂(%) |
| 降血糖类原料药及中间体(%) |
| 降血压类原料及中间体(%) |
| 降血脂类原料药及中间体(%) |
| 抗病毒原料及中间体(%) |
| 抗凝血类原料药及中间体(%) |
| 抗哮喘类原料及中间体(%) |
| 其他(%) |
| 毛利构成(%) |
| CMO(%) |
| 仿制药原料药及中间体(%) |
| 制剂(%) |
| 降血糖类原料药及中间体(%) |
| 降血压类原料及中间体(%) |
| 降血脂类原料药及中间体(%) |
| 抗病毒原料及中间体(%) |
| 抗凝血类原料药及中间体(%) |
| 抗哮喘类原料及中间体(%) |
| 其他(%) |
Showing 1 to 66 of 66 entries